Estrogen receptor of breast cancer stem cells depending on the original breast cancers

Medical Hypotheses

Volumn 77, Issue 1, 2011, Pages 71-73

  Xu, Wei Ru ^a,b   Lin, Hong Sheng ^a   Chen, Xin Yi ^b   Zhang, Ying ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR ALPHA;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASTIC STEM CELLS; RECEPTORS, ESTROGEN;

EID: 79958033468     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.03.028     Document Type: Article

References (42)

1. Ravdin P.M., Cronin K.A., Howlader N., Berg C.D., Chlebowski R.T., Feuer E.J., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007, 356:1670-1674.
2. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988.
3. Patrawala L., Calhoun T., Schneider-Broussard R., Zhou J., Claypool K., Tang D.G. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005, 65:6207-6219.
4. Ponti D., Costa A., Zaffaroni N., Pratesi G., Petrangolini G., Coradini D., et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005, 65:5506-5511.
5. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
6. Charafe-Jauffret E., Ginestier C., Iovino F., Wicinski J., Cervera N., Finetti P., et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69:1302-1313.
7. Kok M., Koornstra R.H., Margarido T.C., Fles R., Armstrong N.J., Linn S.C., et al. Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer. J Pathol 2009, 218:316-326.
8. Howell A., Wardley A.M. Overview of the impact of conventional systemic therapies on breast cancer. Endocr Relat Cancer 2005, 12(Suppl. 1):S9-S16.
9. Ye Y., Xiao Y., Wang W., Yearsley K., Gao J.X., Shetuni B., et al. ERalpha signaling through slug regulates E-cadherin and EMT. Oncogene 2010, 29:1451-1462.
10. Morimoto K., Kim S.J., Tanei T., Shimazu K., Tanji Y., Taguchi T., et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 2009, 100:1062-1068.
11. Gradilone A., Naso G., Raimondi C., Cortesi E., Gandini O., Vincenzi B., et al. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann Oncol 2011, 22:86-92.
12. Zhou L., Jiang Y., Yan T., Di G., Shen Z., Shao Z., et al. The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures. Breast Cancer Res Treat 2010, 122:795-801.
13. Liu S., Ginestier C., Charafe-Jauffret E., Foco H., Kleer C.G., Merajver S.D., et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA 2008, 105:1680-1685.
14. Fehm T., Hoffmann O., Aktas B., Becker S., Solomayer E.F., Wallwiener D., et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009, 11:R59.
15. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
16. Balic M., Lin H., Young L., Hawes D., Giuliano A., McNamara G., et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006, 12:5615-5621.
17. Honeth G., Bendahl P.O., Ringner M., Saal L.H., Gruvberger-Saal S.K., Lovgren K., et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008, 10:R53.
18. Fillmore C.M., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008, 10:R25.
19. Phillips T.M., McBride W.H., Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98:1777-1785.
20. Dontu G., Al-Hajj M., Abdallah W.M., Clarke M.F., Wicha M.S. Stem cells in normal breast development and breast cancer. Cell Prolif 2003, 36(Suppl. 1):59-72.
21. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
22. Pardal R., Clarke M.F., Morrison S.J. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003, 3:895-902.
23. Hope K.J., Jin L., Dick J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004, 5:738-743.
24. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
25. McClanahan T., Koseoglu S., Smith K., Grein J., Gustafson E., Black S., et al. Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. Cancer Biol Ther 2006, 5:419-426.
26. Becker L., Huang Q., Mashimo H. Immunostaining of Lgr5, an intestinal stem cell marker, in normal and premalignant human gastrointestinal tissue. Sci World J 2008, 8:1168-1176.
27. Dontu G., Abdallah W.M., Foley J.M., Jackson K.W., Clarke M.F., Kawamura M.J., et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003, 17:1253-1270.
28. Alvi A.J., Clayton H., Joshi C., Enver T., Ashworth A., Vivanco M.M., et al. Functional and molecular characterisation of mammary side population cells. Breast Cancer Res 2003, 5:R1-R8.
29. Booth B.W., Smith G.H. Estrogen receptor-alpha and progesterone receptor are expressed in label-retaining mammary epithelial cells that divide asymmetrically and retain their template DNA strands. Breast Cancer Res 2006, 8:R49.
30. Clarke R.B., Spence K., Anderson E., Howell A., Okano H., Potten C.S. A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol 2005, 277:443-456.
31. Asselin-Labat M.L., Shackleton M., Stingl J., Vaillant F., Forrest N.C., Eaves C.J., et al. Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst 2006, 98:1011-1014.
32. Sleeman K.E., Kendrick H., Robertson D., Isacke C.M., Ashworth A., Smalley M.J. Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol 2007, 176:19-26.
33. Dontu G., El-Ashry D., Wicha M.S. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 2004, 15:193-197.
34. Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627.
35. Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.M., Sampath J., Morris J.J., et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001, 7:1028-1034.
36. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
37. Clarke R.B., Anderson E., Howell A., Potten C.S. Regulation of human breast epithelial stem cells. Cell Prolif 2003, 36(Suppl. 1):45-58.
38. Sonne-Hansen K., Norrie I.C., Emdal K.B., Benjaminsen R.V., Frogne T., Christiansen I.J., et al. Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance. Breast Cancer Res Treat 2010, 121:601-613.
39. Arpino G., Weiss H., Lee A.V., Schiff R., De Placido S., Osborne C.K., et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005, 97:1254-1261.
40. De Laurentiis M., Arpino G., Massarelli E., Ruggiero A., Carlomagno C., Ciardiello F., et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005, 11:4741-4748.
41. Zhou B.B., Zhang H., Damelin M., Geles K.G., Grindley J.C., Dirks P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009, 8:806-823.
42. Fehm T., Krawczyk N., Solomayer E.F., Becker-Pergola G., Durr-Storzer S., Neubauer H., et al. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 2008, 10:R76.